An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies.

Alison FindlayCraig TurnerHeidi SchilterMandar DeodharWenbin ZhouLara PerrymanJonathan FootAmna ZahoorYimin YaoRoss HamiltonMary BrockChristina RasoJessica StolpMarie GalatiDieter HamprechtBrett CharltonWolfgang Jarolimek

Published in: Clinical and translational medicine (2022)

Keyphrases

small molecule
protein protein
systemic sclerosis
idiopathic pulmonary fibrosis
machine learning